levodopa has been researched along with papaverine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (63.16) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 2 (10.53) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bertolino, A; Di Reda, L; Giovine, A; Livrea, P | 1 |
| Cramer, H; Kiessling, M; Lindl, T | 1 |
| Cooper, DS; Jacobs, LS | 1 |
| Burke, W; Coscia, CJ; Jamroz, G; Lasala, JM; McFarlane, J; Mitchell, J; O'Toole, MM; Wilson, ML | 1 |
| Dougan, D; Mearrick, P; Wade, D | 1 |
| Duvoisin, RC | 1 |
| Posner, DM | 1 |
| Breese, GR; Criswell, HE; Mueller, RA | 1 |
| Cashaw, JL; Davis, VE; Geraghty, CA; McLaughlin, BR | 1 |
| Ane, M; Belin, J; Montastruc, JL; Rascol, A; Rascol, O | 1 |
| Sandler, M | 1 |
| Armando, I; Clow, A; Glover, V; Sandler, M | 1 |
| Petkov, V; Stancheva, S; Yanev, S | 1 |
| Gänsle, A; Moser, A; Scholz, J | 1 |
1 trial(s) available for levodopa and papaverine
| Article | Year |
|---|---|
Does papaverine interact with levodopa in Parkinson's disease?
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Drug Interactions; Female; Humans; Levodopa; Male; Middle Aged; Papaverine; Parkinson Disease; Random Allocation | 1987 |
18 other study(ies) available for levodopa and papaverine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effects of tetrahydropapaveroline on dopamine and 5-hydroxytryptamine metabolism in rat brain in vivo.
Topics: Animals; Brain; Dopamine; Fenclonine; Homovanillic Acid; Isoquinolines; Levodopa; Male; Papaverine; Rats; Serotonin | 1976 |
Cyclic adenosinemonophosphate in cerebrospinal fluid. Effects of theophylline, L-dopa and a dopamine receptor stimulant in rats.
Topics: Animals; Bis(4-Methyl-1-Homopiperazinylthiocarbonyl)disulfide; Cyclic AMP; Dose-Response Relationship, Drug; Levodopa; Male; Papaverine; Phentolamine; Piperazines; Piribedil; Propranolol; Rats; Receptors, Drug; Stimulation, Chemical; Time Factors | 1975 |
Failure of papaverine to alter L-dopa-influenced GH and PRL secretion.
Topics: Adult; Female; Growth Hormone; Humans; Levodopa; Male; Papaverine; Prolactin | 1977 |
Occurrence of a new class of tetrahydroisoquinoline alkaloids in L-dopa-treated parkinsonian patients.
Topics: Animals; Biotransformation; Brain; Carbidopa; Catechols; Humans; Levodopa; Mice; Papaverine; Parkinson Disease; Rats; Tetrahydropapaveroline | 1977 |
Effects of L-dopa metabolites at a dopamine receptor suggest a basis for 'on-off' effect in Parkinson's disease.
Topics: Animals; Dopamine; Dopamine Antagonists; Evoked Potentials; Intestinal Mucosa; Isoquinolines; Levodopa; Mollusca; Muscle Contraction; Papaverine; Parkinson Disease; Receptors, Drug; Stereoisomerism | 1975 |
Antagonism of levodopa by papaverine.
Topics: Aged; Corpus Striatum; Fatigue; Female; Headache; Humans; Hyperhidrosis; Intracranial Arteriosclerosis; Levodopa; Papaverine; Parkinson Disease; Receptors, Drug | 1975 |
Letter: antagonism of levodopa by papaverine.
Topics: Aged; Female; Humans; Levodopa; Papaverine; Parkinson Disease | 1975 |
Pharmacologic evaluation of SCH-39166, A-69024, NO-0756, and SCH-23390 in neonatal-6-OHDA-lesioned rats. Further evidence that self-mutilatory behavior induced by L-dopa is related to D1 dopamine receptors.
Topics: Animals; Animals, Newborn; Benzazepines; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Female; Levodopa; Motor Activity; Oxidopamine; Papaverine; Quinpirole; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Self Mutilation; Sympathectomy, Chemical; Tetrahydroisoquinolines | 1992 |
Effect of acute ethanol administration on brain levels of tetrahydropapaveroline in L-dopa-treated rats.
Topics: Animals; Brain; Dihydroxyphenylalanine; Dopamine; Ethanol; Injections, Intraperitoneal; Levodopa; Male; Papaverine; Rats; Rats, Inbred Strains; Tetrahydropapaveroline; Time Factors | 1987 |
Some anomalies in the L-DOPA response: recent biochemical studies.
Topics: Antiparkinson Agents; Dihydroxyphenylalanine; Dopamine; Humans; Levodopa; Models, Biological; Papaverine; Parkinson Disease | 1974 |
Pictet-Spengler condensation products, stress and alcoholism: some clinical overtones.
Topics: Alcoholism; Animals; Carbolines; Chemical Phenomena; Chemistry; Gas Chromatography-Mass Spectrometry; Humans; Isoquinolines; Levodopa; Monoamine Oxidase Inhibitors; Papaverine; Rats; Salsoline Alkaloids; Stress, Physiological; Substance Withdrawal Syndrome; Tetrahydroisoquinolines; Tetrahydropapaveroline | 1982 |
Effects of glaucine and some glaucine derivatives and of their combination with L-DOPA on the brain level of biogenic monoamines.
Topics: Animals; Aporphines; Biogenic Amines; Brain Chemistry; Dopamine; Kinetics; Levodopa; Male; Norepinephrine; Papaverine; Phosphodiesterase Inhibitors; Rats; Rats, Inbred Strains; Serotonin | 1982 |
Pituitary adenylate cyclase-activating polypeptide (PACAP-27) enhances tyrosine hydroxylase activity in the nucleus accumbens of the rat.
Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; Animals; Cyclic AMP; Dopamine Agents; Enzyme Activation; Female; In Vitro Techniques; Levodopa; Neuropeptides; Nucleus Accumbens; Papaverine; Phosphodiesterase Inhibitors; Pituitary Adenylate Cyclase-Activating Polypeptide; Pituitary Gland; Protein Processing, Post-Translational; Rats; Rats, Wistar; Tyrosine 3-Monooxygenase | 1999 |